Biogen (BIIB) 10-K Summary — Year Ended Dec 31, 2023
Biogen's revenue declined for consecutive periods, and net cash flow from operations decreased significantly after a large acquisition. The company faces ongoing risks from its reliance on legacy products and the uncertain market adoption of a recently approved Alzheimer's treatment.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
Biogen's revenue declined for consecutive periods, and net cash flow from operations decreased significantly after a large acquisition. The company faces ongoing risks from its reliance on legacy products and the uncertain market adoption of a recently approved Alzheimer's treatment.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$9.8B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
$1.2B
Net income reported for the year.
Operating cash flow
$1.5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $11B | n/a |
| Dec 31, 2022 | $10.2B | -7.4% |
| Dec 31, 2023 | $9.8B | -3.3% |
Business overview
Biogen discovers and develops therapies for neurological and neurodegenerative diseases. Its core portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, with a recent approval for an anti-amyloid antibody for early Alzheimer's. The company also collaborates with partners on research and commercialization.
Financial performance
Revenue decreased compared to the prior period, while net income was reported but not broken down into operating income. Cash flow from operations was positive but substantially lower than the previous year, largely due to payments for acquiring a company.
Material risks
The company faces intense competition for its established multiple sclerosis drugs and uncertainty around reimbursement and market uptake of its Alzheimer's treatment. It also relies on a limited number of key products for the majority of its revenue, and any disruption to supply or pricing could materially affect results.
Liquidity and capital
Cash and equivalents dropped sharply after funding a large acquisition, with no share repurchases conducted during the period. A substantial repurchase authorization remained available but unused.
What to watch
Readers should monitor the commercial launch and reimbursement status of the Alzheimer's antibody treatment in major markets outside the United States.